OBJECTIVE: The study investigates the effectiveness of aerosol treatment on gas exchange and pulmonary inflammatory reaction using perfluorocarbons with different molecular structure and vapor pressure. DESIGN: Experimental, prospective, randomized, controlled study. SETTING: Experimental laboratory at a university hospital. SUBJECTS: Twenty anesthetized neonatal piglets assigned to four groups. INTERVENTIONS: After establishment of lung injury by bronchoalveolar lavage, piglets either received aerosolized FC77 (n = 5), perfluorooctylbromide (n = 5), or FC43 (n = 5, 10 mL x kg(-1) x hr(-1) for 2 hrs) or intermittent mandatory ventilation (control, n = 5). Thereafter, animals were supported for another 6 hrs. MEASUREMENTS AND MAIN RESULTS: Pao2 significantly improved in the perfluorocarbon groups compared with control (p < .01). Final Pao2 (mean +/- SEM) was FC77, 406 +/- 27 mm Hg; perfluorooctylbromide, 332 +/- 32 mm Hg; FC43, 406 +/- 19 mm Hg; control, 68 +/- 8 mm Hg. Paco2 and mean pulmonary arterial pressure were lower in all perfluorocarbon groups compared with control. The ratio of terminal dynamic compliance to total compliance was significantly higher in the FC77 than in the FC43, perfluorooctylbromide, and control groups. Relative gene expression of interleukin-1beta, interleukin-8, P-selectin, E-selectin, and intercellular adhesion molecule-1 in lung tissue was determined by TaqMan real time polymerase chain reaction normalized to hypoxanthineguanine-phosphoribosyl-transferase and was shown to be reduced by all perfluorocarbons. CONCLUSIONS: Aerosol treatment with all the perfluorocarbons investigated improved gas exchange and reduced pulmonary inflammatory reaction independently from molecular structure and vapor pressure of the perfluorocarbons. Although differences in vapor pressure and molecular structure may account for varying optimal dosing strategies, several different perfluorocarbons were shown to be principally suitable for aerosol treatment.
OBJECTIVE: The study investigates the effectiveness of aerosol treatment on gas exchange and pulmonary inflammatory reaction using perfluorocarbons with different molecular structure and vapor pressure. DESIGN: Experimental, prospective, randomized, controlled study. SETTING: Experimental laboratory at a university hospital. SUBJECTS: Twenty anesthetized neonatal piglets assigned to four groups. INTERVENTIONS: After establishment of lung injury by bronchoalveolar lavage, piglets either received aerosolized FC77 (n = 5), perfluorooctylbromide (n = 5), or FC43 (n = 5, 10 mL x kg(-1) x hr(-1) for 2 hrs) or intermittent mandatory ventilation (control, n = 5). Thereafter, animals were supported for another 6 hrs. MEASUREMENTS AND MAIN RESULTS:Pao2 significantly improved in the perfluorocarbon groups compared with control (p < .01). Final Pao2 (mean +/- SEM) was FC77, 406 +/- 27 mm Hg; perfluorooctylbromide, 332 +/- 32 mm Hg; FC43, 406 +/- 19 mm Hg; control, 68 +/- 8 mm Hg. Paco2 and mean pulmonary arterial pressure were lower in all perfluorocarbon groups compared with control. The ratio of terminal dynamic compliance to total compliance was significantly higher in the FC77 than in the FC43, perfluorooctylbromide, and control groups. Relative gene expression of interleukin-1beta, interleukin-8, P-selectin, E-selectin, and intercellular adhesion molecule-1 in lung tissue was determined by TaqMan real time polymerase chain reaction normalized to hypoxanthineguanine-phosphoribosyl-transferase and was shown to be reduced by all perfluorocarbons. CONCLUSIONS: Aerosol treatment with all the perfluorocarbons investigated improved gas exchange and reduced pulmonary inflammatory reaction independently from molecular structure and vapor pressure of the perfluorocarbons. Although differences in vapor pressure and molecular structure may account for varying optimal dosing strategies, several different perfluorocarbons were shown to be principally suitable for aerosol treatment.
Authors: Travis Beckett; Laura Bonneau; Alan Howard; James Blanchard; Juan Borda; Daniel J Weiner; Lili Wang; Guang Ping Gao; Jay K Kolls; Rudolf Bohm; Denny Liggitt; Daniel J Weiss Journal: Hum Gene Ther Methods Date: 2012-05-08 Impact factor: 2.396
Authors: Tamer Y El Mays; Parichita Choudhury; Richard Leigh; Emmanuel Koumoundouros; Joanne Van der Velden; Grishma Shrestha; Cora A Pieron; John H Dennis; Francis Hy Green; Ken J Snibson Journal: Respir Res Date: 2014-09-16
Authors: Iñigo Aramendia; Unai Fernandez-Gamiz; Alberto Lopez-Arraiza; Carmen Rey-Santano; Victoria Mielgo; Francisco Jose Basterretxea; Javier Sancho; Miguel Angel Gomez-Solaetxe Journal: Int J Environ Res Public Health Date: 2018-02-28 Impact factor: 3.390
Authors: Veronica Swystun; Francis H Y Green; John H Dennis; Emmanouil Rampakakis; Gurkeet Lalli; Morenike Fadayomi; Andrea Chiu; Grishma Shrestha; Sharif Galal El Shahat; David Evan Nelson; Tamer Y El Mays; Cora A Pieron; Richard Leigh Journal: Trials Date: 2018-06-18 Impact factor: 2.279
Authors: Estibalitz Goikoetxea; Xabier Murgia; Pablo Serna-Grande; Adolf Valls-i-Soler; Carmen Rey-Santano; Alejandro Rivas; Raúl Antón; Francisco J Basterretxea; Lorena Miñambres; Estíbaliz Méndez; Alberto Lopez-Arraiza; Juan Luis Larrabe-Barrena; Miguel Angel Gomez-Solaetxe Journal: PLoS One Date: 2014-09-11 Impact factor: 3.240
Authors: Francis H Y Green; Richard Leigh; Morenike Fadayomi; Gurkeet Lalli; Andrea Chiu; Grishma Shrestha; Sharif G ElShahat; David Evan Nelson; Tamer Y El Mays; Cora A Pieron; John H Dennis Journal: Trials Date: 2016-07-28 Impact factor: 2.279